Trials / Completed
CompletedNCT01724177
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | 25 mg of Lenalidomide administered orally once daily |
Timeline
- Start date
- 2012-11-12
- Primary completion
- 2014-11-20
- Completion
- 2017-03-21
- First posted
- 2012-11-09
- Last updated
- 2018-05-29
- Results posted
- 2016-01-05
Locations
18 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01724177. Inclusion in this directory is not an endorsement.